CIK 0001730430 · Large accelerated filer
Kiniksa Pharmaceuticals International, plc
Sign in to watch- Ticker
- KNSA
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 981795578
- Phone
- 7814319100
- Business address
- 105 PICCADILLY, SECOND FLOOR, LONDON, United Kingdom, W1J 7NJ
- Former names
- Kiniksa Pharmaceuticals, Ltd.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $78,588,440
- in 8 filings, $78.6M under 10b5-1 plans
Net −$78,588,440. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Patel Sanj K −$51.7M CHAIRMAN & CEO sold 42% of stake
- Moat Ross −$9.6M CHIEF OPERATING OFFICER sold 91% of stake
- Paolini John F. −$8.9M CHIEF MEDICAL OFFICER sold 58% of stake
- Megna Michael R −$4.9M CHIEF ACCOUNTING OFFICER sold 80% of stake
- Ragosa Mark −$3.4M CHIEF FINANCIAL OFFICER sold 64% of stake
Reading 59 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-05-01 | Tessari Eben CHIEF OPERATING OFFICER | Grant or award · Performance Share Unit | +5,224 | 5,224 | ||
| 2025-05-01 | Tessari Eben CHIEF OPERATING OFFICER | Grant or award · Performance Share Option | +8,042 | 8,042 | ||
| 2025-05-01 | Tessari Eben CHIEF OPERATING OFFICER | Grant or award · Performance Share Option | +8,302 | 8,302 | ||
| 2025-05-01 | Megna Michael R CHIEF ACCOUNTING OFFICER | Grant or award · Performance Share Unit | +3,270 | 3,270 | ||
| 2025-05-01 | Megna Michael R CHIEF ACCOUNTING OFFICER | Grant or award · Performance Share Unit | +3,433 | 3,433 | ||
| 2025-05-01 | Megna Michael R CHIEF ACCOUNTING OFFICER | Grant or award · Performance Share Option | +5,285 | 5,285 | ||
| 2025-05-01 | Megna Michael R CHIEF ACCOUNTING OFFICER | Grant or award · Performance Share Option | +5,456 | 5,456 | ||
| 2025-05-01 | Ragosa Mark CHIEF FINANCIAL OFFICER | Grant or award · Performance Share Unit | +4,558 | 4,558 | ||
| 2025-05-01 | Ragosa Mark CHIEF FINANCIAL OFFICER | Grant or award · Performance Share Unit | +4,786 | 4,876 | ||
| 2025-05-01 | Ragosa Mark CHIEF FINANCIAL OFFICER | Grant or award · Performance Share Option | +7,368 | 7,368 | ||
| 2025-05-01 | Ragosa Mark CHIEF FINANCIAL OFFICER | Grant or award · Performance Share Option | +7,606 | 7,606 | ||
| 2025-05-01 | Patel Sanj K CHAIRMAN & CEO | Grant or award · Performance Share Unit | +7,987 | 7,987 | ||
| 2025-05-01 | Patel Sanj K CHAIRMAN & CEO | Grant or award · Performance Share Unit | +8,386 | 8,386 | ||
| 2025-05-01 | Patel Sanj K CHAIRMAN & CEO | Grant or award · Performance Share Option | +12,910 | 12,910 | ||
| 2025-05-01 | Patel Sanj K CHAIRMAN & CEO | Grant or award · Performance Share Option | +13,328 | 26,238 | ||
| 2025-05-01 | Paolini John F. CHIEF MEDICAL OFFICER | Grant or award · Performance Share Unit | +4,954 | 4,954 | ||
| 2025-05-01 | Paolini John F. CHIEF MEDICAL OFFICER | Grant or award · Performance Share Unit | +5,201 | 5,201 | ||
| 2025-05-01 | Paolini John F. CHIEF MEDICAL OFFICER | Grant or award · Performance Share Option | +8,007 | 8,007 | ||
| 2025-05-01 | Paolini John F. CHIEF MEDICAL OFFICER | Grant or award · Performance Share Option | +8,266 | 8,266 | ||
| 2025-05-01 | Moat Ross CHIEF COMMERCIAL OFFICER | Option exercise 10b5-1 | +13,406 | $13.35 | $179K | 22,821 |
Page 35 of 74 · 1,467 trades